According to investigate published inside the Aug. 18 early-release problem of the USA facilities for disease manipulate and prevention morbidity and mortality weekly document, the effectiveness of MRNA immunization against covid-19-related hospitalization is sustained over 24 weeks.
In an evaluation in 21 hospitals in 18 states, Mark W. Tedford, M.D., Ph.D., of the cdccovid-19 response team, and co-workers assessed the period of MRNA vaccine efficacy (Pfizer- BioNTech or Moderna) in opposition to covid-19-related hospitalization among adults aged 18 years and older.
The global Intermittent Pneumatic Compression System Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2021-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Intermittent Pneumatic Compression System Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/intermittent-pneumatic-compression-ipc-system-market/download-sampleMarket DynamicsThe growing burden of deep vein thromboses (DVT) drives the demand for intermittent pneumatic compression (IPC) system.
It is the third most common cardiovascular disease and is associated with substantial short-and long‐term morbidity and mortality.
However, public health efforts to measure disease burden and increase awareness of symptoms and risk factors need to improve, particularly in low- and middle-income regions, to address this leading cause of morbidity and mortality.
However, current evidence supporting the use of pneumatic compression devices in peripheral arterial disease is limited; this is because the full potential of intermittent pneumatic compression has not yet been realized, and requires better quality research.